[go: up one dir, main page]

WO2003048204A1 - Gene associe a la maladie d'alzheimer, sa proteine et son utilisation - Google Patents

Gene associe a la maladie d'alzheimer, sa proteine et son utilisation Download PDF

Info

Publication number
WO2003048204A1
WO2003048204A1 PCT/JP2002/012749 JP0212749W WO03048204A1 WO 2003048204 A1 WO2003048204 A1 WO 2003048204A1 JP 0212749 W JP0212749 W JP 0212749W WO 03048204 A1 WO03048204 A1 WO 03048204A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
disease
alzheimer
associated gene
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/012749
Other languages
English (en)
Japanese (ja)
Inventor
Hiroto Komano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JAPAN AS REPRESENTED BY SECRETARY OF CHUBU NATIONAL HOSPITAL
National Institute of Advanced Industrial Science and Technology AIST
Takeda Pharmaceutical Co Ltd
Original Assignee
JAPAN AS REPRESENTED BY SECRETARY OF CHUBU NATIONAL HOSPITAL
Agency of Industrial Science and Technology
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JAPAN AS REPRESENTED BY SECRETARY OF CHUBU NATIONAL HOSPITAL, Agency of Industrial Science and Technology, Takeda Chemical Industries Ltd filed Critical JAPAN AS REPRESENTED BY SECRETARY OF CHUBU NATIONAL HOSPITAL
Priority to AU2002354433A priority Critical patent/AU2002354433A1/en
Publication of WO2003048204A1 publication Critical patent/WO2003048204A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un gène régulant la production de la protéine bêta-amyloïde, sa protéine et son utilisation. De manière plus spécifique, l'invention concerne entre autres un gène régulant la production de la protéine bêta-amyloïde, une protéine codée par ce gène ou son sel, un anticorps dirigé contre cette protéine, un diagnostic ou un médicament faisant appel à cet anticorps, ainsi qu'un procédé de criblage d'un composé s'avérant efficace pour traiter la maladie d'Alzheimer au moyen de ladite protéine.
PCT/JP2002/012749 2001-12-06 2002-12-05 Gene associe a la maladie d'alzheimer, sa proteine et son utilisation Ceased WO2003048204A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002354433A AU2002354433A1 (en) 2001-12-06 2002-12-05 Alzheimer's disease-associated gene and protein and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-373050 2001-12-06
JP2001373050 2001-12-06

Publications (1)

Publication Number Publication Date
WO2003048204A1 true WO2003048204A1 (fr) 2003-06-12

Family

ID=19181834

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/012749 Ceased WO2003048204A1 (fr) 2001-12-06 2002-12-05 Gene associe a la maladie d'alzheimer, sa proteine et son utilisation

Country Status (2)

Country Link
AU (1) AU2002354433A1 (fr)
WO (1) WO2003048204A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104580A1 (fr) 2007-03-01 2008-09-04 Probiodrug Ag Nouvelle utilisation d'inhibiteurs de la glutaminyl cyclase
WO2011029920A1 (fr) 2009-09-11 2011-03-17 Probiodrug Ag Dérivés hétérocycliques en tant qu'inhibiteurs de glutaminyle cyclase
WO2011107530A2 (fr) 2010-03-03 2011-09-09 Probiodrug Ag Nouveaux inhibiteurs
WO2011110613A1 (fr) 2010-03-10 2011-09-15 Probiodrug Ag Inhibiteurs hétérocycliques de la glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (fr) 2010-04-21 2011-10-27 Probiodrug Ag Nouveaux inhibiteurs
WO2012123563A1 (fr) 2011-03-16 2012-09-20 Probiodrug Ag Dérivés de benzimidazole en tant qu'inhibiteurs de la glutaminyl cyclase
EP2865670A1 (fr) 2007-04-18 2015-04-29 Probiodrug AG Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase
EP3461819A1 (fr) 2017-09-29 2019-04-03 Probiodrug AG Inhibiteurs de la glutaminyl-cyclase

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058356A1 (fr) * 1999-03-26 2000-10-05 Human Genome Sciences, Inc. 50 proteines secretees d'origine humaine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058356A1 (fr) * 1999-03-26 2000-10-05 Human Genome Sciences, Inc. 50 proteines secretees d'origine humaine

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] KOMANO H. ET AL.: "A new functional screening system identified cDNA which increase gamma-cleavage", XP002965865, accession no. DIALOG Database accession no. 200100482637 *
DATABASE BIOSIS [online] SAI X. ET AL.: "ER stress- induced membrane-associated protein increases gamma-cleavage", XP002965866, accession no. DIALOG Database accession no. 200100552012 *
KOMANO H. ET AL.: "A new functional screening system for identification of regulators for the generation of amyloid beta-protein", J. BIOL. CHEM., vol. 277, no. 42, October 2002 (2002-10-01), pages 39627 - 39633, XP002965868 *
SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 1, November 2001 (2001-11-01), pages 1439 *
SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 1, November 2001 (2001-11-01), pages 512 *
SUDOH S. ET AL.: "Intracellular site of gamma-secretase cleavage for Abeta42 generation in neuro 2a cells harbouring a presenilin 1 mutation", EUR. J. BIOCHEM., vol. 267, no. 7, April 2000 (2000-04-01), pages 2036 - 2045, XP002951097 *
TOUCHOT N. ET AL.: "Biochemical properties of the YPT-related rab1B protein comparison with rab1A", FEBS LETT., vol. 256, no. 1-2, 1989, pages 79 - 84, XP002965867 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104580A1 (fr) 2007-03-01 2008-09-04 Probiodrug Ag Nouvelle utilisation d'inhibiteurs de la glutaminyl cyclase
EP2481408A2 (fr) 2007-03-01 2012-08-01 Probiodrug AG Nouvelle utilisation d'inhibiteurs glutaminyle cyclase
EP2865670A1 (fr) 2007-04-18 2015-04-29 Probiodrug AG Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase
WO2011029920A1 (fr) 2009-09-11 2011-03-17 Probiodrug Ag Dérivés hétérocycliques en tant qu'inhibiteurs de glutaminyle cyclase
WO2011107530A2 (fr) 2010-03-03 2011-09-09 Probiodrug Ag Nouveaux inhibiteurs
WO2011110613A1 (fr) 2010-03-10 2011-09-15 Probiodrug Ag Inhibiteurs hétérocycliques de la glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (fr) 2010-04-21 2011-10-27 Probiodrug Ag Nouveaux inhibiteurs
WO2012123563A1 (fr) 2011-03-16 2012-09-20 Probiodrug Ag Dérivés de benzimidazole en tant qu'inhibiteurs de la glutaminyl cyclase
EP3461819A1 (fr) 2017-09-29 2019-04-03 Probiodrug AG Inhibiteurs de la glutaminyl-cyclase

Also Published As

Publication number Publication date
AU2002354433A1 (en) 2003-06-17

Similar Documents

Publication Publication Date Title
WO2005061545A3 (fr) Methode
WO2003014162A1 (fr) Anticorps reconnaissant la proteine beta-amyloide liee au ganglioside gm1, et adn codant l'anticorps
WO2004074232A8 (fr) Derives d'acide 1-phenylalcane-carboxylique pour le traitement de maladies neurodegeneratives
WO2002096415A3 (fr) Procedes pour traiter la maladie d'alzheimer et/ou pour reguler les niveaux de peptides beta-amyloides chez un sujet
EP2465872A3 (fr) Anticorps anti-ADDL et leurs utilisations
EP1765388B8 (fr) Therapie combinee pour la prevention ou le traitement de la maladie d'alzheimer, et kit correspondant
AU2003220096A1 (en) Methods for alzheimer's disease treatment and cognitive enhancement
EP2305286A3 (fr) Traitement de la maladie d' Alzheimer
WO2006014638A3 (fr) Anticorps anti-oligomeres reticules de la proteine $g(b)-amyloide
WO2003007803A3 (fr) Procedes servant a diagnostiquer et a traiter la maladie d'alzheimer et la maladie de parkinson
WO2003028631A3 (fr) Cibles medicamenteuses destinees a la maladie d'alzheimer et a d'autres maladies associees a une diminution du metabolisme neuronal
WO2003001983A3 (fr) Methodes de diagnostic et de traitement d'une maladie mediee par une fonction diminuee de mmp-2
AU2002330215A1 (en) Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
WO2003048204A1 (fr) Gene associe a la maladie d'alzheimer, sa proteine et son utilisation
WO2007021886A3 (fr) Compositions de memapsine 2 tronquee et traitements associes
WO2005006949A3 (fr) Methodes de prediction du developpement de maladies auto-immunes et traitement associe
CA2534643A1 (fr) Procedes de detection et d'identification de composes
AU2003273310A1 (en) Substituted aminoethers for the treatment of alzheimer's disease
WO2003012141A1 (fr) Procede de recherche/criblage du gene associe a la maladie d'alzheimer
WO2007067512A3 (fr) Procede pour identifier des modulateurs d'adprh convenant pour traiter la maladie d'alzheimer
WO2004005540A3 (fr) Utilisations de substances qui se lient a ngal pour le diagnostic et le traitement de maladies cancereuses
WO2006091964A3 (fr) Regulateurs de mauvais repliement et d'agregation de proteine et procedes d'utilisation
WO2005023979A3 (fr) Molecules d'acide nucleique de s. mansoni isolees et utilisations associees
WO2003028536A3 (fr) Methodes permettant de diagnostiquer et de traiter les maladies cardiaques
WO2005002573A3 (fr) Methodes d'utilisation de modulateurs de tyrosine kinase 2 riche en proline

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP